Literature DB >> 22196318

Fragile X syndrome and attention-deficit/hyperactivity disorder symptoms.

Presenter Swapna Deshpande1, Discussant Barbara J Coffey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22196318      PMCID： PMC3279710          DOI： 10.1089/cap.2011.2164

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN： 1044-5463            Impact factor:   2.576


× No keyword cloud information.
  11 in total

1.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.

Authors:  A J Verkerk; M Pieretti; J S Sutcliffe; Y H Fu; D P Kuhl; A Pizzuti; O Reiner; S Richards; M F Victoria; F P Zhang
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

Review 2.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice.

Authors:  Kevin Y Miyashiro; Andrea Beckel-Mitchener; T Patrick Purk; Kevin G Becker; Tanya Barret; Lei Liu; Salvatore Carbonetto; Ivan Jeanne Weiler; William T Greenough; James Eberwine
Journal:  Neuron       Date:  2003-02-06       Impact factor: 17.173

Review 4.  Psychopharmacology in fragile X syndrome--present and future.

Authors:  Elizabeth Berry-Kravis; Kristina Potanos
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004

Review 5.  Attention and language in fragile X.

Authors:  Kim Cornish; Vicki Sudhalter; Jeremy Turk
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004

Review 6.  Recognizing the role of parents in developmental outcomes: a systems approach to evaluating the child with developmental disabilities.

Authors:  Lara S Head; Leonard Abbeduto
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2007

Review 7.  New insights into fragile X syndrome: from molecules to neurobehaviors.

Authors:  Peng Jin; Stephen T Warren
Journal:  Trends Biochem Sci       Date:  2003-03       Impact factor: 13.807

Review 8.  Fragile X syndrome.

Authors:  Kathryn B Garber; Jeannie Visootsak; Stephen T Warren
Journal:  Eur J Hum Genet       Date:  2008-04-09       Impact factor: 4.246

Review 9.  FMR1 and the fragile X syndrome: human genome epidemiology review.

Authors:  D C Crawford; J M Acuña; S L Sherman
Journal:  Genet Med       Date:  2001 Sep-Oct       Impact factor: 8.822

10.  A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

Authors:  E Berry-Kravis; D Hessl; S Coffey; C Hervey; A Schneider; J Yuhas; J Hutchison; M Snape; M Tranfaglia; D V Nguyen; R Hagerman
Journal:  J Med Genet       Date:  2009-01-06       Impact factor: 6.318
View more
  3 in total

1.  EXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome.

Authors:  Frank Haessler; Franziska Gaese; Michael Colla; Michael Huss; Christoph Kretschmar; Marc Brinkman; Heike Schieb; Helmut Peters; Samuel Elstner; David Pittrow
Journal:  BMC Psychiatry       Date:  2013-12-19       Impact factor: 3.630

2.  EEG Signal Complexity Is Reduced During Resting-State in Fragile X Syndrome.

Authors:  Mélodie Proteau-Lemieux; Inga Sophia Knoth; Kristian Agbogba; Valérie Côté; Hazel Maridith Barlahan Biag; Angela John Thurman; Charles-Olivier Martin; Anne-Marie Bélanger; Cory Rosenfelt; Flora Tassone; Leonard J Abbeduto; Sébastien Jacquemont; Randi Hagerman; François Bolduc; David Hessl; Andrea Schneider; Sarah Lippé
Journal:  Front Psychiatry       Date:  2021-11-11       Impact factor: 4.157

3.  Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.

Authors:  Frank Haessler; Franziska Gaese; Michael Huss; Christoph Kretschmar; Marc Brinkman; Helmut Peters; Samuel Elstner; Michael Colla; David Pittrow
Journal:  BMC Psychiatry       Date:  2016-09-10       Impact factor: 3.630
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.